Disclaimer: This article looks into the novel research of the clinical applications of ketamine in the treatment of depression. This article is in no way a promotion of recreational drug use, but rather an insight into the steps being taken to improve the psychopharmacology related to depression. It is important to note that the doses given during the experimental ketamine trials which will be discussed in this article are far below that of street doses, standing at a minute 0.5mg/kg.
It is often suggested that drugs can play an aiding role in the development of mental disorders. Heavy cannabis use, for example, has been found to have the potential of doubling the risk of schizophrenia diagnosis in individuals who start taking the drug below the age of 18 (Moore et al., 2007). These types of findings have allowed the development of a negative stigma around the use of any and all types of street drugs. The dopamine hypothesis supports the notion that neurotransmitter dysfunctions can cause mental instabilities, and can present themselves in various forms, including the showing of psychotic symptoms. Many street drugs tend to affect these neurotransmitters, and it would therefore be plausible to say that they can play a role in mental disorders such as depression. However, is this role always a negative one?